Kemnay Advisory Services’s Ascendis Pharma A/S ASND Stock Holding History

Kemnay Advisory Services’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,756	Closed	-$556K	–	82
2020 Q2	$556K	Buy	+3,756	New	+$516K	0.08%	55
2019 Q4	–	Sell	-9,367	Closed	-$902K	–	72
2019 Q3	$902K	Buy	+9,367	New	+$1.04M	0.23%	50

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Kemnay Advisory Services's ASND Position: Q3 2020 in Review

Kemnay Advisory Services sold out of Ascendis Pharma A/S (ASND) in Q3 2020, closing a stake of 3,756 shares — an estimated $556K sold.

Kemnay Advisory Services first reported a position in ASND in Q3 2019 and held it in 2 quarters. The position peaked at $902K in Q3 2019. 152 funds tracked by Wall St. Rank hold ASND as of Q3 2020.

Kemnay Advisory Services reported no remaining Ascendis Pharma A/S position as of Q3 2020 after selling out during the quarter.
Kemnay Advisory Services sold 3,756 Ascendis Pharma A/S shares in Q3 2020, an estimated $556K.
Kemnay Advisory Services first reported a position in Ascendis Pharma A/S in Q3 2019 and held it in 2 quarters.
Kemnay Advisory Services's Ascendis Pharma A/S position peaked at $902K in Q3 2019.
152 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2020.

Based on Kemnay Advisory Services's 13F filing for Q3 2020, filed 16 Nov 2020.